Acne Clinical Trial
Official title:
6 Month Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Small Particle Hyaluronic Acid to Treat Acne Scars Located on the Cheeks and Forehead
Verified date | May 2019 |
Source | Schweiger Dermatology, PLLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55 years old of all skin types will be asked to sign an informed consent form prior to any study procedures. Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk or Placebo) in each scar at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline (Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit visit). The treatment area will be evaluated at each visit by the unblinded investigator regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness, smoothness, and clarity. Safety and adverse events will be captured at each visit only by the unblinded investigator.
Status | Terminated |
Enrollment | 26 |
Est. completion date | April 18, 2019 |
Est. primary completion date | April 18, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 22 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Male or non-pregnant female subjects on an acceptable form of birth control aged 22-55 years of age. 2. Willing to refrain from undergoing any procedures to repair or augment any acne scar in the treatment area during the study. 3. Female subjects with a negative pregnancy test confirmed at screening and on an acceptable form of birth control. Acceptable forms of birth control on this study include oral or injectable contraceptive, contraceptive patches, Depo-Provera, NuvaRing, Implanon, double barrier methods, IUD, same sex partner, or abstinence. Males will be required to use an acceptable method of birth control: vasectomy, double-barrier method, condom with spermicidal lube, or abstinence. 4. Signed informed consent prior to conducting any study procedures. 5. Willing to refrain from undergoing any cosmetic procedures in the treatment area during the study. 6. At least one acne scar located on the cheeks or forehead to be = 3 mm and = 10 mm in diameter, and rated as =3 on the ASRS at day 0. Subjects may have up to three qualifying acne scars determined eligible for treatment at screening. 7. Acne scars that are classified as either ice pick, rolling, or boxcar acne scars. 8. =15 pustules/papules on the face at the time of screening and = 2 nodules, and no cysts at Baseline. 9. Willing to attend all study visits and comply with protocol Exclusion Criteria: 1. Subjects with active cystic acne at screening (> 2 nodules or any cysts present at Baseline). 2. Use of antibiotics 2-weeks prior to screening. 3. Use of retinoids 2-weeks prior to screening. 4. Use of salicylic acid or benzoyl peroxide 7 days prior to screening. 5. Excessive facial hair, skin conditions, facial tattoos, or other dermatologic marks that would obscure the treatment area. 6. Use of Isotretinoin (Accutane) 6 months prior to screening. 7. Semi-permanent or permanent injection in the face 3 months prior to screening. 8. History of bleeding disorders. 9. Use of blood thinners (i.e warfarin (Coumadin), clopidogrel bisulfate (Plavix), etc.) 1 month prior to screening. 10. Acne scars that are considered post-inflammatory erythematous, post-inflammatory hyperpigmentation, varicella (chicken pox) scars, or perifollicular elastolysis will not be allowed to be identified as the target acne scars. These types of scars are still allowed to be present but cannot be selected. 11. Acne scars that are located in the glabella and temple regions. Acne scars located in these regions will not be allowed to be selected as a target or additional acne scar. As well, scars located in these areas will not be allowed to be treated during the study. Subjects are allowed to have acne scars located in these areas but cannot have them selected for evaluation or treated during the study. 12. Laser or light (red and blue) treatments for acne 3 months prior to screening. 13. Resurfacing procedures (CO2 , Erbium, Fraxel, etc.) performed 6 months prior to screening. 14. Any chemical peels in the last 30 days prior to screening. 15. Hypersensitivity to amid-type local anesthetics. 16. Any cortisol steroid or ILK injection 30 days prior to screening 17. Subjects with a history of diabetes. 18. Any medical condition or diagnosis which in the investigator's opinion would disqualify them from the research study. 19. History of abuse with the use of alcohol or drugs. 20. Participation in a clinical trial or use of an investigational product in the past 30 days. 21. Subjects who are considered health risks for participation in the study or the investigator determines not to be suitable. |
Country | Name | City | State |
---|---|---|---|
United States | Schweiger Dermatology, PLLC | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Schweiger Dermatology, PLLC |
United States,
Brandt FS, Cazzaniga A. Hyaluronic acid fillers: Restylane and Perlane. Facial Plast Surg Clin North Am. 2007 Feb;15(1):63-76, vii. Review. — View Citation
Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging. 2008;3(1):153-9. Review. — View Citation
Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. 2008 Jun;34 Suppl 1:S92-9. doi: 10.1111/j.1524-4725.2008.34249.x. Review. — View Citation
Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998 Dec;24(12):1317-25. — View Citation
Fife D, Zachary CB. Combining techniques for treating acne scars. Current Dermatology Reports. 2012;1:82-88.
Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. J Clin Aesthet Dermatol. 2011 Aug;4(8):50-7. — View Citation
Hession MT, Graber EM. Atrophic acne scarring: a review of treatment options. J Clin Aesthet Dermatol. 2015 Jan;8(1):50-8. Review. — View Citation
Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001 Jul;45(1):109-17. Review. — View Citation
Koo JY, Smith LL. Psychologic aspects of acne. Pediatr Dermatol. 1991 Sep;8(3):185-8. Review. — View Citation
Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994 Jul;19(4):303-8. — View Citation
Lizzul PF, Narurkar VA. The role of calcium hydroxylapatite (Radiesse) in nonsurgical aesthetic rejuvenation. J Drugs Dermatol. 2010 May;9(5):446-50. Review. — View Citation
Rivera AE. Acne scarring: a review and current treatment modalities. J Am Acad Dermatol. 2008 Oct;59(4):659-76. doi: 10.1016/j.jaad.2008.05.029. Epub 2008 Jul 26. Review. — View Citation
Sadick NS, Palmisano L. Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat. 2009;20(5):302-7. doi: 10.1080/09546630902817879. — View Citation
Tsao SS, Dover JS, Arndt KA, Kaminer MS. Scar management: keloid, hypertrophic, atrophic, and acne scars. Semin Cutan Med Surg. 2002 Mar;21(1):46-75. Review. — View Citation
Werschler, P. (2016). Severe - Depth = >2.5 mm in depth. Visibility = Substantial shadowing with tangential lighting. Journal of Drugs in Dermatology, 15(5), 518-525
Werschler, Phillip, et al.
* Note: There are 16 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Statistically significant acne scar area reduction from baseline. | The first exploratory endpoint is a significant reduction of acne scar area as measured by the VECTRA system 6 months post first treatment | Baseline-6 Months post first injection. | |
Primary | 1 grade improvement of ASRS from baseline | The primary endpoint is a one grade improvement of the acne scar from baseline as rated on the ASRS. | Baseline-6 Months post first injection. | |
Secondary | Statistically significant improvement of the acne scar from baseline | A significant improvement of the acne scar from baseline as rated by the | Baseline-6 Months post first injection. | |
Secondary | Statistically significant improvement of the skin quality from baseline | A significant improvement of the skin quality of the treatment area as rated by the investigator using the skin quality assessment scale. | Baseline-6 Months post first injection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05097157 -
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
|
N/A | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT04806594 -
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
|
N/A | |
Recruiting |
NCT03465150 -
Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
|
||
Completed |
NCT02250859 -
A Pharmacokinetic Study of Minocycline in Male and Female Volunteers
|
Phase 1 | |
Completed |
NCT01206348 -
Combination Treatment for Moderate to Severe Acne
|
Phase 4 | |
Terminated |
NCT01193764 -
Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris
|
N/A | |
Completed |
NCT00725439 -
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
|
Phase 2 | |
Completed |
NCT05640388 -
Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
|
||
Completed |
NCT04873089 -
Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
|
||
Recruiting |
NCT05941065 -
Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin
|
N/A | |
Recruiting |
NCT06120452 -
A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation
|
N/A | |
Completed |
NCT04300010 -
Blue Light Therapy of C. Acnes
|
Phase 4 | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Completed |
NCT04559022 -
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
|
N/A | |
Terminated |
NCT02431494 -
Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris
|
N/A | |
Completed |
NCT05469880 -
Efficacy and Tolerance of Formula 609613 37 in Acneic Patients
|
N/A | |
Completed |
NCT02944461 -
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01951417 -
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
|
Phase 4 | |
Completed |
NCT01701024 -
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
|
Phase 3 |